Graft Versus Host Disease Market Overview
The Graft Versus Host Disease market continues to witness robust growth across the 7MM (the US, EU4, the UK, and Japan). According to DelveInsight’s analysis, the GvHD market was valued at approximately USD 2.1 billion in 2025 and is poised for significant expansion through the forecast period.
Key highlights driving this growth:
- Rising Graft Versus Host Disease diagnosed patient populations and increasing adoption of emerging therapeutic approaches are primary growth drivers
- The therapeutic landscape is increasingly shaped by targeted and cell-based therapies, with key agents – ruxolitinib (JAKAFI/JAKAVI), Ibrutinib (IMBRUVICA), and remestemcel-L (RYONCIL/TEMCELL HS) – playing a central role across the 7MM
- In 2025, ruxolitinib leads in revenue generation, followed by REZUROCK
- Emerging pipeline therapies including MaaT013 (XERVYTEG), RGI-2001, and CYP-001 are expected to shape the future landscape, with some anticipated to enter the US market by 2028
- The US holds the largest Graft Versus Host Disease market share at ~USD 1.6 billion in 2025, expected to account for approximately 77% of the 7MM total by 2036
- Approximately 52,000 total GvHD cases were reported across the 7MM in 2025, with the patient pool projected to increase through 2036 driven by rising HSCT procedures and improved survival rates
- In the US, 2025 type-specific cases included ~4,300 acute GvHD cases and ~18,500 five-year prevalent chronic GvHD cases
- Current GvHD prophylaxis faces limitations in high-risk transplant settings due to suboptimal efficacy and long-term toxicities, underscoring the need for safer, more targeted prophylactic approaches
Graft Versus Host Disease Therapies
The current GvHD therapeutic armamentarium includes a range of approved agents addressing both acute and chronic disease forms:
- Ruxolitinib (JAKAFI/JAKAVI)
- Ibrutinib (IMBRUVICA)
- Remestemcel-L (RYONCIL/TEMCELL HS)
- and others.
These agents collectively anchor the present market landscape and continue to drive Graft Versus Host Disease market trends through evolving clinical adoption and expanding label indications.
Partner with DelveInsight to identify unmet opportunities and drive strategic decisions in the evolving Graft Versus Host Disease treatment landscape.
GvHD Overview and Diagnosis
GvHD is a complex immune-mediated condition occurring following allogeneic HSCT, in which donor-derived immune cells recognize recipient tissues as foreign and mount an immune response. The condition most commonly affects the skin, liver, and gastrointestinal tract, and is broadly classified into acute and chronic forms. Clinical presentations vary widely – from mild localized involvement to severe, systemic complications that significantly impact patient outcomes and quality of life.
Diagnosis of GvHD requires a comprehensive and systematic approach, integrating clinical evaluation with histopathological and laboratory findings. It begins with identification of characteristic signs and symptoms across affected organs, followed by tissue biopsy for confirmation in many cases. Laboratory parameters and imaging studies further support evaluation of organ involvement and disease severity, enabling accurate classification and timely clinical decision-making.
Graft Versus Host Disease Unmet Needs
The Graft Versus Host Disease market research conducted by DelveInsight identifies critical gaps between current patient care and ideal disease management. These unmet needs continue to drive investment in next-generation therapeutic development:
- Improved early diagnosis and risk stratification remain a priority, as late identification limits therapeutic effectiveness
- Limited understanding of chronic GvHD (cGvHD) pathophysiology continues to constrain targeted drug development
- Lack of optimized combinatorial therapy strategies hinders durable disease control
- Need for novel therapies that offer both efficacy and improved tolerability beyond current standards
Graft Versus Host Disease Epidemiology Insights in the 7MM
Key findings from GvHD epidemiological analysis and forecast, as part of comprehensive Graft Versus Host Disease market insight:
- In 2025, the 7MM recorded ~7,100 cases of Grade B (II) acute GvHD, ~1,800 cases of Grade C (III), and ~700 cases of Grade D (IV), with all figures expected to increase by 2036
- In the US, acute GvHD cases by organ involvement in 2025 were primarily observed in the skin (~3,700 cases), followed by the gastrointestinal tract (~2,100 cases) and the liver (~1,300 cases)
- In Japan, chronic GvHD cases by organ involvement in 2025 reflected diverse multi-organ disease: skin (~4,000), oral mucosa (~3,100), lungs (~2,400), liver (~3,000), eyes (~1,900), gastrointestinal tract (~1,000), joints and fascia (~400), and genitals (~300)
Graft Versus Host Disease Approved Therapies
Ruxolitinib (JAKAFI/JAKAVI) – Incyte/Novartis
Ruxolitinib is an oral selective JAK1/2 inhibitor that modulates the JAK-STAT pathway to reduce cytokine-driven inflammation. It is indicated for steroid-refractory acute and chronic GvHD in patients aged 12 years and older after failure of one or two prior systemic therapies.
- August 2023: Novartis received approval for ruxolitinib as JAKAVI in Japan for GvHD following HSCT
- May 2022: The European Commission approved ruxolitinib (JAKAVI) for aGvHD and cGvHD patients with inadequate response to corticosteroids or other systemic therapies
- September 2021: The US FDA approved ruxolitinib (JAKAFI) for cGvHD after failure of one or two prior systemic therapies in patients aged 12 years and older
Ibrutinib (IMBRUVICA) – AbbVie (Pharmacyclics)/Janssen
Ibrutinib is an oral, once-daily BTK inhibitor that blocks B-cell signaling and reduces abnormal immune activity, indicated for cGvHD after failure of one or more prior systemic therapies.
- August 2022: The US FDA approved IMBRUVICA for pediatric patients ≥1 year of age with cGvHD after failure of one or more systemic therapy lines
- September 2021: The PMDA approved IMBRUVICA to treat cGvHD after HSCT
- August 2017: The US FDA first approved IMBRUVICA for adult patients with cGvHD after failure of one or more systemic therapy lines
Graft Versus Host Disease Companies
The competitive landscape of the Graft Versus Host Disease market includes a diverse array of pharmaceutical and biopharmaceutical players:
- AbbVie
- Johnson and Johnson
- Sanofi
- Incyte
- Syndax Pharmaceuticals
- Novartis
- Neovii
- Mundipharma
- Platinum Life Excellence Biotech
- Shionogi
- JCR Pharmaceuticals
- Bristol Myers Squibb
- And more.
Graft Versus Host Disease Drug Updates
The Graft Versus Host Disease pipeline continues to advance with several promising agents across clinical stages:
- MaaT013 (XERVYTEG) is being evaluated in a pivotal Phase III trial for corticosteroid- and ruxolitinib-refractory GI acute GvHD; DSMB review of the ARES study confirmed a favorable benefit–risk profile with high efficacy and low toxicity
- RGI-2001 completed a Phase II clinical trial (NCT04014790) in 2022 for prevention of aGvHD following alloHSCT, building on an earlier Phase I/II trial (NCT01379209) completed in 2015
- CYP-001 was evaluated in a global Phase II clinical trial (NCT05643638), comparing it in combination with corticosteroids versus corticosteroids alone for high-risk acute GvHD under a cleared US FDA IND
Graft Versus Host Disease Market Outlook
Graft Versus Host Disease remains a serious and potentially life-threatening immune-mediated condition arising after allogeneic HSCT, resulting in multi-organ involvement most commonly affecting the skin, liver, and gastrointestinal tract. Its complex immunopathology, significant impact on survival and quality of life, and the increasing number of transplant procedures continue to elevate the disease burden across the 7MM.
Key marketed therapies shaping current management include:
- Belumosudil (REZUROCK; Sanofi/Meiji Seika Pharmaceuticals): An oral, first-in-class selective ROCK2 inhibitor approved by the US FDA in July 2021 for cGvHD after failure of at least two prior systemic therapies. It downregulates STAT3, upregulates STAT5, reduces Type 17 and follicular T-helper cells, and enhances regulatory T-cell function
- Axatilimab-csfr (NIKTIMVO; Incyte/Syndax): A first-in-class monoclonal antibody targeting CSF-1R, granted US FDA approval in August 2024 for cGvHD following inadequate response to at least two prior systemic treatments; it reduces pathogenic inflammation and fibrosis central to cGvHD
The Graft Versus Host Disease market stands at a pivotal transformation point. Historically defined by corticosteroid-centered, empirically layered immunosuppression, management has long relied on reactive and symptom-driven strategies with limited durability. A new generation of mechanism-specific therapies – spanning precision biologics, cell-based immunomodulators, and microbiome-restorative agents – is now reshaping the landscape toward prevention, immune tolerance, and tissue repair across the 7MM from 2022–2036, with strong commercial implications for both marketed products and emerging pipelines.
In 2025, the US dominated the GvHD market, accounting for 77% of total 7MM revenue. The Graft Versus Host Disease Market Size in the US was valued at USD 2.1 billion, driven largely by the anticipated impact of emerging therapies on future market growth.
Access DelveInsight’s comprehensive Graft Versus Host Disease market report to unlock clinical, epidemiological, and competitive intelligence for GvHD today.
Conclusion
The Graft Versus Host Disease (GvHD) market is expanding rapidly, driven by rising patient prevalence, advancing therapies, and a strong clinical pipeline. In 2025, the market surpassed USD 2.1 billion across the 7MM, led by the United States. Novel targeted therapies, including ruxolitinib, belumosudil, and axatilimab-csfr, are transforming treatment beyond traditional immunosuppression. Emerging pipeline candidates such as MaaT013, RGI-2001, and CYP-001 offer hope for refractory cases. Increasing incidence of acute and chronic GvHD highlights the need for continued innovation. Opportunities remain in early diagnosis, risk stratification, and combination therapy optimization, positioning precision medicine as a key driver of future market growth.
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharmaceutical companies by providing comprehensive end-to-end solutions to improve their performance. It also offers healthcare consulting services that leverage market analysis to accelerate business growth and overcome challenges with practical approaches.
Media contact
Name: Abhishek kumar
E-mail:abhishek@delveinsight.com
